CG Oncology, Inc.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for patients with bladder cancer in the United States. The company's lead product candidate, cretostimogene, is being evaluated in multiple clinical trials, including phase 2 and phase 3 studies for various types of non-muscle invasive bladder cancer (NMIBC). Specifically, it is studied in patients with high-risk NMIBC after BCG failure, as monotherapy for BCG-unresponsive NMIBC, and for intermediate-risk NMIBC following TURBT. CG Oncology also has a phase 2 trial for high-risk NMIBC in BCG-exposed and BCG-naïve patients. The company was formerly known as Cold Genesys, Inc. before rebranding in June 2020.

CG Oncology, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CGON. Its shares are traded in United States Dollars (USD), as the company is based in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for the company's stock.

CG Oncology operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing innovative therapies for cancer, particularly bladder cancer. The biotechnology industry involves using biological processes and organisms to create medical treatments, and CG Oncology's work with oncolytic immunotherapy exemplifies this approach.

CG Oncology, Inc. is headquartered in Dallas, Texas, United States. The company was founded in 2010 and was originally known as Cold Genesys, Inc. before rebranding to CG Oncology in June 2020. Its operations are primarily focused on the US market, where it develops and aims to commercialize its bladder cancer therapies.

CG Oncology is a late-stage clinical biopharmaceutical company that generates revenue by developing and commercializing its product candidate, cretostimogene grenadenorepvec, for bladder cancer. As a development-stage company, it does not yet have approved products on the market, so it currently does not generate revenue from product sales. Instead, it focuses on advancing its clinical trials to achieve regulatory approval. Its portfolio includes multiple phase 2 and phase 3 trials for various NMIBC indications, such as high-risk NMIBC after BCG failure, BCG-unresponsive NMIBC, and intermediate-risk NMIBC. Upon successful approval, the company would generate revenue from sales of cretostimogene in the US.